Skip to main content
Shiven Patel, MD, Oncology, Rexburg, ID, MadisonHealth

ShivenBharatPatelMDMBA, FACP

Oncology Rexburg, ID

Hematologic Oncology, Thoracic Cancer

Physician

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Patel's full profile

Already have an account?

Education & Training

  • Indiana University – Purdue University Indianapolis
    Indiana University – Purdue University IndianapolisM.B.A., Business of Medicine Program, 2015 - 2017
  • University of Utah Health
    University of Utah HealthFellowship, Hematology and Medical Oncology, 2012 - 2015
  • University of Maryland
    University of MarylandResidency, Internal Medicine, 2008 - 2011
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 2008
  • University of Florida
    University of FloridaB.S., Major: Basic Biology and Medicine; Minor: Business Administration, 2001 - 2004
  • University of Florida
    University of FloridaA.A., 2001 - 2003

Certifications & Licensure

  • UT State Medical License
    UT State Medical License 2012 - 2026
  • ID State Medical License
    ID State Medical License 2017 - 2024
  • MD State Medical License
    MD State Medical License 2011 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Anderson Scholar University of Florida College of Liberal Arts and Sciences, 2004
  • Junior Honors Medical Program University of Florida College of Medicine, 2003
  • Presidential Ceremony Honoree University of Florida, 2003
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma  
    Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N, BMC Urology, 1/1/2017
  • Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular en...  
    Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N, Journal of Oncology Pharmacy Practice, 1/1/2017
  • Myeloid Growth Factors, Version 22017, NCCN Clinical Practice Guidelines in Oncology  
    Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fyan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S..., Journal of the National Comprehensive Cancer Network, 1/1/2017
  • Join now to see all

Abstracts/Posters

  • Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic...
    Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N, Journal of Clinical Oncology, 1/1/2017
  • Association of single nucleotide polymorphisms (SNPs) in STS and SULT2B1 and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive pros...
    Agarwal N, Buckley TH, Farnham JM, Patel SB, Agarwal A, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Alex A, Cannon-Albright LA, Clinical Cancer Research, 1/1/2016
  • Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory pr...
    Agarwal N, Heemers H, Farnham JM, Patel SB, Gill DM, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA, Journal of Clinical Oncology, 1/1/2016
  • Join now to see all

Lectures

  • Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Oncologic Emergencies 
    1/1/2018
  • Lung Cancer 
    Veterans Affairs Hospital, University of Utah - 1/1/2017
  • Join now to see all

Press Mentions

  • The Biggest Reimbursement Challenges in Oncology: 6 Leaders Weigh In
    The Biggest Reimbursement Challenges in Oncology: 6 Leaders Weigh InDecember 7th, 2020
  • Navigating Treatment Decisions with Immunotherapy in Squamous NSCLC
    Navigating Treatment Decisions with Immunotherapy in Squamous NSCLCOctober 11th, 2019
  • Conference Coverage: NCCN Policy Summit
    Conference Coverage: NCCN Policy SummitAugust 17th, 2019
  • Join now to see all

Hospital Affiliations